transmembrane protein 147Genealiases: NEDFLPH · NIFIE14
Q-omics provides the consensus-scored TMEM147 profile across patient tissues and cancer cell-line models. TMEM147 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TMEM147 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, TMEM147 RNA expression shows 19,363 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, BLCA, and ACC as cancer lineages where TMEM147 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM147 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM147 survival associations across molecular data types. TMEM147 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM147 RNA expression–survival associations across cancer types. High TMEM147 expression shows unfavorable associations in MESO, LIHC, ACC, UVM, LGG and CESC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TMEM147 RNA expression.
This table summarizes TMEM147 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM147. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM147 shows higher tumor expression in BLCA, COAD, LIHC, LUAD, STAD and UCEC. The BLCA box plot shows higher TMEM147 RNA expression in tumor versus normal tissue (log2 FC = +1.276, t-test p < 0.001).
This table shows molecular features associated with TMEM147 in patient tissues and cancer cell lines. In patient samples, TMEM147 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM147 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
